A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Sponsor and Collaborators
Janssen Inc.
Contact
Click here for contact info
Investigator
Janssen Inc. Clinical Trial
Janssen Inc.
ClinicalTrials.gov Identifier
NCT01484275
Please login or register first to view this content.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.